BBM:CA:CNSX-Blueberries Medical Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 0.07

Change

-0.01 (-7.14)%

Market Cap

CAD 0.01B

Volume

0.02M

Avg Analyst Target

CAD 0.39 (+500.00%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Blueberries Medical Corp (BBM) Stock Analysis:
Based on the Blueberries Medical Corp stock forecasts from 1 analysts, the average analyst target price for Blueberries Medical Corp is CAD 0.39 over the next 12 months. Blueberries Medical Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Blueberries Medical Corp is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Blueberries Medical Corp’s stock price was CAD 0.07. Blueberries Medical Corp’s stock price has changed by +0.00% over the past week, +0.01% over the past month and +0.00% over the last year.

About

Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquartered in Bogotá, Colombia. Addre ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

-0.09 (-0.82%)

CAD7.32B N/A 32.60
TRUL:CA Trulieve Cannabis Corp

-0.08 (-0.25%)

CAD6.00B 36.17 20.67
GTII:CA Green Thumb Industries Inc

-0.18 (-0.70%)

CAD5.85B 61.14 20.34
VRNO:CA Verano Holdings Corp

-0.38 (-2.37%)

CAD3.25B 21.75 22.36
CL:CA Cresco Labs Inc

-0.34 (-3.92%)

CAD2.37B N/A 20.98
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
CCHW:CA Columbia Care Inc

-0.04 (-0.98%)

CAD1.49B N/A 127.53
AYR-A:CA Ayr Wellness Inc

-0.21 (-1.00%)

CAD1.40B N/A N/A
TER:CA TerrAscend Corp

+0.15 (+2.07%)

CAD1.34B N/A 81.47
JUSH:CA Jushi Holdings Inc

-0.04 (-0.79%)

CAD1.01B N/A N/A

ETFs Containing BBM:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.14% 31% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.14% 31% F 33% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.01B 44% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.12 48% F 58% F
Price / Cash Flow Ratio -4.80 50% F 33% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.26% 65% D 62% D-
Return on Invested Capital -64.43% 32% F 41% F
Return on Assets -16.52% 53% F 69% D+
Debt to Equity Ratio 21.53% 33% F 24% F
Technical Ratios  
Short Ratio 0.95 22% F 21% F
Short Percent 0.22% 13% F 14% F
Beta 1.71 30% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.